The Tourette Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tourette Syndrome. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Tourette Syndrome by seven companies/universities/institutes. The top development phase for Tourette Syndrome is preclinical with three drugs in that stage. The Tourette Syndrome pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Tourette Syndrome pipeline products market are: National Institute of Neurological Disorders and Stroke, Asarina Pharma and Emalex Biosciences.
The key targets in the Tourette Syndrome pipeline products market include cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, Cannabinoid Receptor 2, and Cannabinoid Receptor 1.
The key mechanisms of action in the Tourette Syndrome pipeline product include cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A Inhibitor with two drugs in Phase II. The Tourette Syndrome pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Tourette Syndrome pipeline products market including Small Molecule.
Tourette Syndrome overview
Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called “tics”. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age and sex. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications, and behavior therapy.
For a complete picture of Tourette Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
